Nutritional and therapeutic approaches for protecting human gut microbiota from psychotropic treatments

被引:15
作者
Chait, Yasmina Ait [1 ]
Mottawea, Walid [1 ,2 ]
Tompkins, Thomas A. [3 ]
Hammami, Riadh [1 ]
机构
[1] Univ Ottawa, Sch Nutr Sci, NuGut Res Platform, Fac Hlth Sci, Ottawa, ON K1N 6N5, Canada
[2] Mansoura Univ, Dept Microbiol & Immunol, Fac Pharm, Mansoura, Egypt
[3] Rosell Inst Microbiome & Probiot, Montreal, PQ H4P 2R2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Gut microbiota; Gut-brain axis; Antipsychotics; Dysbiosis; Probiotics; Prebiotics; INTERNATIONAL SCIENTIFIC ASSOCIATION; SEROTONIN REUPTAKE INHIBITORS; FECAL MICROBIOTA; INTESTINAL MICROBIOTA; ANTIMICROBIAL PROPERTIES; INSULIN SENSITIVITY; CONSENSUS STATEMENT; METABOLIC SYNDROME; IN-VITRO; MECHANISMS;
D O I
10.1016/j.pnpbp.2020.110182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Emerging evidence highlighted the essential role played by the microbiota-gut-brain axis in maintaining human homeostasis, including nutrition, immunity, and metabolism. Much recent work has linked the gut microbiota to many psychiatric and neurodegenerative disorders such as depression, schizophrenia, and Alzheimer?s disease. Shared gut microbiota alterations or dysbiotic microbiota have been identified in these separate disorders relative to controls. Much attention has focused on the bidirectional interplay between the gut microbiota and the brain, establishing gut dysbiotic status as a critical factor in psychiatric disorders. Still, the antibiotic-like effect of psychotropic drugs, medications used for the treatment of these disorders, on gut microbiota is largely neglected. In this review, we summarize the current findings on the impact of psychotropics on gut microbiota and how their antimicrobial potency can trigger dysbiosis. We also discuss the potential therapeutic strategies, including probiotics, prebiotics, and fecal transplantation, to attenuate the dysbiosis related to psychotropics intake.
引用
收藏
页数:11
相关论文
共 121 条
[1]   The Placenta Harbors a Unique Microbiome [J].
Aagaard, Kjersti ;
Ma, Jun ;
Antony, Kathleen M. ;
Ganu, Radhika ;
Petrosino, Joseph ;
Versalovic, James .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (237)
[2]   Human Gut Microbiome and Risk for Colorectal Cancer [J].
Ahn, Jiyoung ;
Sinha, Rashmi ;
Pei, Zhiheng ;
Dominianni, Christine ;
Wu, Jing ;
Shi, Jianxin ;
Goedert, James J. ;
Hayes, Richard B. ;
Yang, Liying .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (24) :1907-1911
[3]  
[Anonymous], 2018, UNDERSTANDING DEPRES
[4]  
Ayaz M, 2015, ACTA POL PHARM, V72, P1269
[5]   Sertraline enhances the activity of antimicrobial agents against pathogens of clinical relevance [J].
Ayaz, Muhammad ;
Subhan, Fazal ;
Ahmed, Jawad ;
Khan, Arif-ullah ;
Ullah, Farhat ;
Ullah, Ihsan ;
Ali, Gowhar ;
Syed, Nawazish-i-Husain ;
Hussain, Sajid .
JOURNAL OF BIOLOGICAL RESEARCH-THESSALONIKI, 2015, 22
[6]   Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children [J].
Bahr, S. M. ;
Tyler, B. C. ;
Wooldridge, N. ;
Butcher, B. D. ;
Burns, T. L. ;
Teesch, L. M. ;
Oltman, C. L. ;
Azcarate-Peril, M. A. ;
Kirby, J. R. ;
Calarge, C. A. .
TRANSLATIONAL PSYCHIATRY, 2015, 5 :e652-e652
[7]   Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure [J].
Bahr, Sarah M. ;
Weidemann, Benjamin J. ;
Castro, Ana N. ;
Walsh, John W. ;
Deleon, Orlando ;
Burnett, Colin M. L. ;
Pearson, Nicole A. ;
Murry, Daryl J. ;
Grobe, Justin L. ;
Kirby, John R. .
EBIOMEDICINE, 2015, 2 (11) :1725-1734
[8]   A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) [J].
Barker, Anna K. ;
Duster, Megan ;
Valentine, Susan ;
Hess, Timothy ;
Archbald-Pannone, Laurie ;
Guerrant, Richard ;
Safdar, Nasia .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (11) :3177-3180
[9]   Antibiotic-Induced Changes in the Intestinal Microbiota and Disease [J].
Becattini, Simone ;
Taur, Ying ;
Pamer, Eric G. .
TRENDS IN MOLECULAR MEDICINE, 2016, 22 (06) :458-478
[10]  
Bermon S, 2015, EXERC IMMUNOL REV, V21, P70